Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AstraZeneca Expands Amyloidosis Portfolio with $780M Neurimmune Deal

AstraZeneca Expands Amyloidosis Portfolio with $780M Neurimmune Deal

AstraZeneca has significantly bolstered its presence in the amyloidosis treatment landscape, announcing a new licensing agreement with Swiss biotech firm Neurimmune. The deal, which could reach $780 million, centers on NI009, a preclinical monoclonal antibody targeting light chain (AL) amyloidosis.

NoahAI News12/4/2025
CHS Sells Lab Assets to Labcorp for $194M, Reshaping Healthcare Landscape

CHS Sells Lab Assets to Labcorp for $194M, Reshaping Healthcare Landscape

Community Health Systems (CHS) has finalized the sale of its ambulatory outpatient laboratory services to Labcorp for approximately $194 million in cash before transaction expenses. This strategic move, initially announced in July, marks a significant shift in the healthcare industry landscape, affecting operations across 13 states.

NoahAI News12/4/2025
Capricor's Deramiocel Shows Promise in Phase III Trial for Duchenne Muscular Dystrophy Cardiomyopathy

Capricor's Deramiocel Shows Promise in Phase III Trial for Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics has announced positive results from its pivotal Phase III HOPE-3 trial for deramiocel, a cell therapy targeting Duchenne muscular dystrophy (DMD) cardiomyopathy. The treatment demonstrated significant benefits in both upper-limb function and cardiac function, potentially addressing a critical unmet need in DMD patient care.

NoahAI News12/4/2025
FDA Leadership Exodus Raises Concerns for Pharmaceutical Industry

FDA Leadership Exodus Raises Concerns for Pharmaceutical Industry

The U.S. Food and Drug Administration (FDA) is facing unprecedented turnover in its senior leadership, sparking worry throughout the pharmaceutical industry about regulatory stability and America's competitive edge in biotechnology. Recent departures, including those of key figures Peter Marks and Richard Pazdur, have left just three veterans remaining from the agency's senior organizational chart from a year ago.

NoahAI News12/4/2025
Medtronic Launches Innovative Insulin Delivery System with Abbott Partnership

Medtronic Launches Innovative Insulin Delivery System with Abbott Partnership

Medtronic, a leader in medical technology, has begun the U.S. rollout of its latest insulin pump system, marking a significant advancement in diabetes management technology. The MiniMed 780G insulin pump, now integrated with Abbott's Instinct sensor, represents a groundbreaking collaboration between two industry giants and a departure from Medtronic's traditional approach of pairing its pumps with in-house continuous glucose monitors (CGMs).

NoahAI News12/4/2025
Bristol Myers Squibb Delays Key Alzheimer's Psychosis Trial for Cobenfy Amid Site Irregularities

Bristol Myers Squibb Delays Key Alzheimer's Psychosis Trial for Cobenfy Amid Site Irregularities

Bristol Myers Squibb (BMS) has announced a significant delay in the readout of its closely watched ADEPT-2 trial, evaluating the drug Cobenfy for Alzheimer's disease psychosis. The pharmaceutical giant cited "irregularities" in trial execution at some study sites, pushing the expected results to 2026.

NoahAI News12/4/2025
Akura Medical Secures $53M in Series C Funding to Advance Thrombectomy Technology

Akura Medical Secures $53M in Series C Funding to Advance Thrombectomy Technology

Akura Medical, a California-based medical device company, has successfully closed a $53 million Series C financing round to accelerate the development of its innovative thrombectomy technologies. The funding, led by Qatar Investment Authority, will support the advancement of Akura's Katana thrombectomy system and NavIQ procedural planning software, both aimed at improving blood clot removal procedures.

NoahAI News12/4/2025
FDA Scales Back Animal Testing Requirements for Certain Antibody Therapies

FDA Scales Back Animal Testing Requirements for Certain Antibody Therapies

The U.S. Food and Drug Administration (FDA) has announced plans to reduce or eliminate testing on non-human primates for specific antibody therapies, marking a significant shift in the agency's approach to drug evaluation. This move aligns with the FDA's broader initiative to transition away from animal experiments in favor of more advanced, human-relevant testing methods.

NoahAI News12/4/2025
Cosmo Pharmaceuticals Reveals Promising Phase 3 Results for Male Pattern Hair Loss Treatment

Cosmo Pharmaceuticals Reveals Promising Phase 3 Results for Male Pattern Hair Loss Treatment

Cosmo Pharmaceuticals has announced groundbreaking results from two phase 3 trials for its topical cream clascoterone, potentially revolutionizing the treatment of male pattern hair loss. The studies, involving 1,465 participants across 50 sites in Europe and the U.S., demonstrated significant improvements in hair growth compared to placebo.

NoahAI News12/4/2025
Capricor's Duchenne Cell Therapy Achieves Breakthrough in Phase 3 Trial, Setting Stage for FDA Approval

Capricor's Duchenne Cell Therapy Achieves Breakthrough in Phase 3 Trial, Setting Stage for FDA Approval

Capricor Therapeutics has made a significant leap forward in the treatment of Duchenne muscular dystrophy (DMD) with its cell therapy, deramiocel, achieving remarkable success in a pivotal Phase 3 trial. The results have not only revitalized the company's prospects but also ignited hope for patients suffering from this debilitating genetic disorder.

NoahAI News12/4/2025
Medtronic Reshapes Acute Care and Monitoring Business with Key Appointment

Medtronic Reshapes Acute Care and Monitoring Business with Key Appointment

Medtronic, a leading medical technology company, has announced a significant leadership change in its acute care and monitoring business. The move comes as part of a broader restructuring effort within the company, signaling a renewed focus on innovation and growth in this crucial segment.

NoahAI News12/4/2025
AI-Driven M&A Acceleration Expected in Medtech Industry for 2026

AI-Driven M&A Acceleration Expected in Medtech Industry for 2026

The medtech industry is poised for significant growth and transformation in 2026, with artificial intelligence (AI) playing a pivotal role in driving merger and acquisition (M&A) activity. According to a recent outlook report by PitchBook, strategic investors are showing renewed optimism and targeting companies approaching clinical milestones in key areas such as cardiology, orthopedics, and diagnostics.

NoahAI News12/4/2025
«1...262728...67»